Estudos Randomizados

Estudo randomizado | Resumos diários de cuidados por escrito para familiares de pacientes críticos.

6 Set, 2022 | 12:40h

Daily Written Care Summaries for Families of Critically Ill Patients: A Randomized Controlled Trial – Critical Care Medicine

Editorial: More Documentation? Who Needs It? – Critical Care Medicine

 

---

Estudo randomizado | Autoaferição de pressão arterial com um dispositivo padrão não é melhorada pelo uso de um aplicativo de smartphone.

29 Ago, 2022 | 17:57h

Effectiveness of Standard vs Enhanced Self-measurement of Blood Pressure Paired With a Connected Smartphone Application: A Randomized Clinical Trial – JAMA Internal Medicine (link para o resumo – $ para o texto completo)

Comunicado de imprensa: For Checking Blood Pressure at Home, Basic Cuffs Are Just as Good – UC San Francisco

Comentário: App-enabled device no better than standard device for self-measuring blood pressure – ACP Internist

 

Comentário no Twitter

Monitoring #bloodpressure at home may help with #bloodpressurecontrol, but using an enhanced device pairing with a smartphone application appears to be no more effective than using a standard device. https://t.co/h6zREImCNv #Research pic.twitter.com/T1zWDlp2pC

— JAMA Internal Medicine (@JAMAInternalMed) August 15, 2022

 

---

Estudo randomizado | Autoamostragem de HPV entre não participantes de rastreamento de câncer de colo do útero.

29 Ago, 2022 | 17:54h

HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial – British Journal of Cancer

 

Comentário no Twitter

Pragmatic randomised controlled trial of 3 different HPV screening approaches suggests that opt-in and particularlly send-to-all self-sampling increased participation among long-term, higher-risk non-attenders: https://t.co/hBouqoBMnU #GynCSM #hsronc

— NatureRevClinOncol (@NatRevClinOncol) August 25, 2022

 

---

Estudo randomizado | Eficácia da suplementação do potássio sobre o risco de peritonite em pacientes hipopotassêmicos em diálise peritoneal.

29 Ago, 2022 | 17:51h

Efficacy of Potassium Supplementation in Hypokalemic Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial – American Journal of Kidney Diseases (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

Efficacy of Potassium Supplementation in Hypokalemic Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trialhttps://t.co/DlEUJJUPr4@PD_Perls @DWJohnsonNeph #VisualAbstract pic.twitter.com/9D0VifCPMb

— AJKD (@AJKDonline) May 23, 2022

 

---

Análise secundária de um estudo randomizado | Efeitos da empagliflozina sobre sintomas, limitações físicas e qualidade de vida de pacientes internados com insuficiência cardíaca aguda.

29 Ago, 2022 | 17:50h

Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial – Circulation

Comentário: Empagliflozin Offers Clinical Benefit in Heart Failure – HealthDay

Estudo original: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial – Nature Medicine

 

---

Estudo randomizado | Talimogene Laherparepvec com pembrolizumabe não é melhor que placebo-pembrolizumabe em pacientes com melanoma avançado.

29 Ago, 2022 | 17:35h

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma – Journal of Clinical Oncology

 

---

Resultados de longo prazo de um estudo randomizado | Lenalidomida com rituximabe vs. rituximabe em quimioterapia seguida de rituximabe de manutenção no linfoma folicular avançado não tratado.

29 Ago, 2022 | 17:27h

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R²) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma – Journal of Clinical Oncology

Comentários:

First-Line Lenalidomide/Rituximab vs Rituximab/Chemotherapy With Rituximab Maintenance for Advanced Follicular Lymphoma – The ASCO Post

Lenalidomide Plus Rituximab Represents Acceptable Chemo-Free Alternative for Untreated Advanced Follicular Lymphoma – OncLive

 

Comentário no Twitter

6-year update from the phase III RELEVANCE trial of lenalidomide-rituximab versus rituximab-chemotherapy in previously untreated patients with advanced-stage follicular lymphoma demonstrates very similar durable efficacy and safety: https://t.co/rMeA2tOoO6 #lymsm #hemeonc

— NatureRevClinOncol (@NatRevClinOncol) August 19, 2022

 

---

Estudo randomizado | Em pacientes com dor neuropática diabética, a amitriptilina suplementada com pregabalina, a pregabalina suplementada com amitriptilina e a duloxetina suplementada com pregabalina foram similarmente efetivas.

29 Ago, 2022 | 17:24h

Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial – The Lancet

 

---

Estudo randomizado | Olokizumabe vs. placebo ou adalimumabe na artrite reumatoide.

29 Ago, 2022 | 17:13h

Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário: Novel IL-6 Blocker Matches Humira in Rheumatoid Arthritis – MedPage Today (necessário cadastro gratuito)

 

---

Estudos randomizados | Ublituximabe vs. teriflunomida na esclerose múltipla recorrente.

29 Ago, 2022 | 17:11h

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis – New England Journal of Medicine (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

In two parallel randomized trials in patients with MS, ublituximab resulted in lower relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not affect disability. https://t.co/fpdtYhTNER pic.twitter.com/EPJEetSVdS

— NEJM (@NEJM) August 24, 2022

 

---